Based in Portland, Oregon, Calypte takes its name from Calypte anna, a humming bird with brilliant emerald and ruby feathers that makes its home on the west coast of  North America

CALYPTE BIOMEDICAL CORPORATION

Calypte Biomedical Corporation develops in vitro testing products to improve the diagnosis of Human Immunodeficiency Virus (HIV) infection, sexually transmitted diseases and other chronic diseases.Aware™ HIV-1/2 OMT is such type of product.Our innovative product line includes both point-of-care rapid tests and traditional EIA diagnostic tests.

Founded in 1988, Calypte is a pioneer in non-blood-based HIV antibody testing. We’re the first and only company to earn approval from the U.S. Food and Drug Administration for a urine-based HIV-1 antibody-screening test and supplemental Western blot.Today, our Aware™ family of rapid oral fluid HIV tests offers unrivalled HIV 1/2 testing flexibility in a non-laboratory setting.

Calypte is also the licensed manufacturer of a quantitative enzyme immunoassay developed by the U.S. Centers for Disease Control and Prevention (CDC) that can discriminate between recent and established HIV-1 infections. Designed for use in epidemiology, the Aware™ BED™ EIA is a practical way to determine HIV-1 incidence (the rate of new infections). Because it uses cross-sectional rather than longitudinal sampling and is based on direct biomarker evaluation, the BED EIA can provide incidence information much more rapidly than traditional methods such as cohort studies.  Since its introduction in 2004 (formerly under the name BED HIV-1 Incidence EIA), the Aware™ BED™ EIA has gained widespread favor with government institutions and HIV intervention programs worldwide as a tool for better allocating resources, measuring program success and targeting HIV hot spots.

Working through a network of national and regional distributors Calypte continues to broaden the reach of its products. We plan to launch a new line of rapid HIV antibody tests in the United States and other developed nations using a novel lateral flow platform technology and we remain committed to bringing new products to developing regions where the need is acute for accurate, innovative HIV testing methods.

To meet this demand with maximum quality and efficiency, we’ve added manufacturing capacity through a contract with an ISO-certified manufacturer in Thailand and a cGMP certified manufacturer in the USA.

Publicly held, Calypte trades on the OTCBB under the symbol “CBMC.”

Home

Downloads

Terms of use

Privacy Policy

Site Map

Contact us

Home

Calypte

Products

Technologies

Investors

Contact us

Home

Calypte

Products

Technologies

Investors

Contact us